Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
American Society of Tropical Medicine and Hygiene
2017
|
| _version_ | 1826265334980542464 |
|---|---|
| author | Minassian, AM Silk, SE Poulton, ID Mitton, CH Jin, J Diouf, A Querol-Rubiera, A Bisnauthsing, K Ogrina, T Payne, RO Folegatti, P Silman, D Batra, R Brendish, N Taylor, IJ Smith, R Berrie, E Morelle, D Lievens, M Noe, AR Soisson, LA Ashfield, R Long, CA Goodman, AL Faust, SN Nugent, FL Lawrie, AM Draper, SJ |
| author_facet | Minassian, AM Silk, SE Poulton, ID Mitton, CH Jin, J Diouf, A Querol-Rubiera, A Bisnauthsing, K Ogrina, T Payne, RO Folegatti, P Silman, D Batra, R Brendish, N Taylor, IJ Smith, R Berrie, E Morelle, D Lievens, M Noe, AR Soisson, LA Ashfield, R Long, CA Goodman, AL Faust, SN Nugent, FL Lawrie, AM Draper, SJ |
| author_sort | Minassian, AM |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T20:22:04Z |
| format | Conference item |
| id | oxford-uuid:2e266e0c-02d9-4c4a-9abc-2c5338750351 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:22:04Z |
| publishDate | 2017 |
| publisher | American Society of Tropical Medicine and Hygiene |
| record_format | dspace |
| spelling | oxford-uuid:2e266e0c-02d9-4c4a-9abc-2c53387503512022-03-26T12:47:27ZSafety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trialConference itemhttp://purl.org/coar/resource_type/c_5794uuid:2e266e0c-02d9-4c4a-9abc-2c5338750351Symplectic Elements at OxfordAmerican Society of Tropical Medicine and Hygiene2017Minassian, AMSilk, SEPoulton, IDMitton, CHJin, JDiouf, AQuerol-Rubiera, ABisnauthsing, KOgrina, TPayne, ROFolegatti, PSilman, DBatra, RBrendish, NTaylor, IJSmith, RBerrie, EMorelle, DLievens, MNoe, ARSoisson, LAAshfield, RLong, CAGoodman, ALFaust, SNNugent, FLLawrie, AMDraper, SJ |
| spellingShingle | Minassian, AM Silk, SE Poulton, ID Mitton, CH Jin, J Diouf, A Querol-Rubiera, A Bisnauthsing, K Ogrina, T Payne, RO Folegatti, P Silman, D Batra, R Brendish, N Taylor, IJ Smith, R Berrie, E Morelle, D Lievens, M Noe, AR Soisson, LA Ashfield, R Long, CA Goodman, AL Faust, SN Nugent, FL Lawrie, AM Draper, SJ Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial |
| title | Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial |
| title_full | Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial |
| title_fullStr | Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial |
| title_full_unstemmed | Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial |
| title_short | Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial |
| title_sort | safety and immunogenicity of the novel plasmodium falciparum blood stage vaccine rh5 1 as01b in a phase i iia clinical trial |
| work_keys_str_mv | AT minassianam safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT silkse safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT poultonid safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT mittonch safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT jinj safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT dioufa safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT querolrubieraa safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT bisnauthsingk safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT ogrinat safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT paynero safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT folegattip safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT silmand safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT batrar safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT brendishn safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT taylorij safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT smithr safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT berriee safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT morelled safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT lievensm safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT noear safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT soissonla safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT ashfieldr safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT longca safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT goodmanal safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT faustsn safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT nugentfl safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT lawrieam safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial AT drapersj safetyandimmunogenicityofthenovelplasmodiumfalciparumbloodstagevaccinerh51as01binaphaseiiiaclinicaltrial |